Liver Cancer Genesis, Progression and Metastasis
Hepatocellular carcinoma (HCC) is a common tumor type arising from several distinct etiologies. It is usually diagnosed late and is difficult to treat. This volume presents an overview of selected aspects of HCC pathogenesis, and research aimed at developing diagnostic biomarkers. It points to a num...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_113358 | ||
| 005 | 20230905 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230905s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a intechopen.100845 | ||
| 020 | |a 9781803564142 | ||
| 020 | |a 9781803564135 | ||
| 020 | |a 9781803564159 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.5772/intechopen.100845 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Feitelson, Mark |4 edt | |
| 700 | 1 | |a Arzumanyan, Alla |4 edt | |
| 700 | 1 | |a Feitelson, Mark |4 oth | |
| 700 | 1 | |a Arzumanyan, Alla |4 oth | |
| 245 | 1 | 0 | |a Liver Cancer |b Genesis, Progression and Metastasis |
| 260 | |b IntechOpen |c 2023 | ||
| 300 | |a 1 electronic resource (146 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Hepatocellular carcinoma (HCC) is a common tumor type arising from several distinct etiologies. It is usually diagnosed late and is difficult to treat. This volume presents an overview of selected aspects of HCC pathogenesis, and research aimed at developing diagnostic biomarkers. It points to a number of putative therapeutic targets, including signal transduction pathways, metabolic and epigenetic alterations in tumor cells, the tumor microenvironment, the gut microbiome, and functions of immune effector cells. Given the multi-step nature of most cancers, including HCC, future drug development will most likely require combination therapies that will simultaneously target multiple steps in hepatocarcinogenesis. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |4 https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a liver cirrhosis | ||
| 653 | |a inflammation | ||
| 653 | |a biomarkers | ||
| 653 | |a immunotherapy | ||
| 653 | |a gene expression | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mts.intechopen.com/storage/books/11596/authors_book/authors_book.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/113358 |7 0 |z DOAB: description of the publication |